South African biopharmaceutical company The Biovac Institute will manufacture and distribute Pfizer and BioNTech’s COVID-19 vaccine in Africa, with the three companies signing a letter of intent this week.
Coriolis Pharma has announced a 7,800-meter-square expansion to a building situated in Munich, Germany, where the company is headquartered, that will host formulation development for advanced therapeutic medicine products (ATMPs).
Ontario-based, Nicoya Lifesciences, is in the process of completing a prototype of a low-cost, single-use device that tests for active SARS-CoV-2 infection, variants and, eventually, other viruses. The novel test is called Atlas.
US biopharma firm, TG Therapeutics, has announced an expanded contract manufacturing deal with Samsung Biologics to support the production of its investigational anti-CD20 monoclonal antibody, ublituximab.
UK company, Spirea, a spin-out from the University of Cambridge, which was founded to deliver the next generation of antibody drug conjugate (ADC) cancer therapeutics, has secured financing from o2h Ventures and Syndicate Room.
Upstream processes were the focus of most early applications of continuous bioprocessing. That is now changing, with many biologic manufacturers evaluating downstream continuous processing and suppliers preparing their portfolios for the anticipated pivot...
Special Edition: The Future of Continuous BioProcessing
The shift away from batch downstream processing has moved closer in recent years amid progress on techniques such as antibody purification using continuous chromatography media. However, there remain barriers to clear before manufacturing facilities that...
Vibalogics has announced it is expanding its global footprint with a late phase clinical and commercial manufacturing facility near Boston, Massachusetts, a major milestone as it looks to advance its services to drug developers across the globe.
The UK’s Vaccines Manufacturing & Innovation Centre (VMIC) announces that the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the second of two GMP COVID-19 vaccine manufacturing suites located at Oxford Biomedica's...
Lonza adds its first sterile drug product fill-finish facility to its network after acquiring Novartis’ Swiss plant, building on its parenteral drug product development and testing capabilities for clinical trial supply.